X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with FDC LTD. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs FDC LTD. - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA FDC LTD. SHASUN PHARMA/
FDC LTD.
 
P/E (TTM) x 123.9 21.2 583.2% View Chart
P/BV x 8.5 4.8 178.6% View Chart
Dividend Yield % 0.2 1.0 23.5%  

Financials

 SHASUN PHARMA   FDC LTD.
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
FDC LTD.
Mar-14
SHASUN PHARMA/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs94144 65.6%   
Low Rs4679 57.7%   
Sales per share (Unadj.) Rs214.247.6 450.3%  
Earnings per share (Unadj.) Rs5.37.6 70.1%  
Cash flow per share (Unadj.) Rs15.89.0 175.6%  
Dividends per share (Unadj.) Rs1.002.25 44.4%  
Dividend yield (eoy) %1.42.0 70.7%  
Book value per share (Unadj.) Rs53.347.5 112.2%  
Shares outstanding (eoy) m56.62177.83 31.8%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x0.32.3 14.0%   
Avg P/E ratio x13.114.6 89.6%  
P/CF ratio (eoy) x4.412.3 35.8%  
Price / Book Value ratio x1.32.3 56.0%  
Dividend payout %18.729.6 63.4%   
Avg Mkt Cap Rs m3,95819,784 20.0%   
No. of employees `000NANA-   
Total wages/salary Rs m2,1641,221 177.3%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m12,1278,459 143.4%  
Other income Rs m229394 58.3%   
Total revenues Rs m12,3568,852 139.6%   
Gross profit Rs m1,0092,070 48.7%  
Depreciation Rs m594249 238.3%   
Interest Rs m41531 1,338.6%   
Profit before tax Rs m2302,184 10.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-225 0.1%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-73606 -12.0%   
Profit after tax Rs m3021,353 22.3%  
Gross profit margin %8.324.5 34.0%  
Effective tax rate %-31.727.7 -114.2%   
Net profit margin %2.516.0 15.6%  
BALANCE SHEET DATA
Current assets Rs m6,8844,355 158.1%   
Current liabilities Rs m8,4561,792 471.9%   
Net working cap to sales %-13.030.3 -42.8%  
Current ratio x0.82.4 33.5%  
Inventory Days Days6244 138.6%  
Debtors Days Days10825 436.0%  
Net fixed assets Rs m4,9703,025 164.3%   
Share capital Rs m113179 63.4%   
"Free" reserves Rs m2,8758,243 34.9%   
Net worth Rs m3,0208,453 35.7%   
Long term debt Rs m1,81711 16,985.0%   
Total assets Rs m13,34710,557 126.4%  
Interest coverage x1.671.4 2.2%   
Debt to equity ratio x0.60 47,538.1%  
Sales to assets ratio x0.90.8 113.4%   
Return on assets %5.413.1 41.0%  
Return on equity %10.016.0 62.5%  
Return on capital %13.323.5 56.7%  
Exports to sales %46.413.3 348.3%   
Imports to sales %14.23.3 426.1%   
Exports (fob) Rs m5,6221,126 499.4%   
Imports (cif) Rs m1,728283 610.9%   
Fx inflow Rs m5,8431,146 509.8%   
Fx outflow Rs m2,173355 611.6%   
Net fx Rs m3,669791 464.0%   
CASH FLOW
From Operations Rs m3981,485 26.8%  
From Investments Rs m-1,635-620 263.9%  
From Financial Activity Rs m1,309-753 -173.9%  
Net Cashflow Rs m71113 63.1%  

Share Holding

Indian Promoters % 39.2 68.9 56.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 4.7 76.6%  
FIIs % 17.6 7.5 234.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 19.0 208.4%  
Shareholders   20,750 23,730 87.4%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   DR. REDDYS LAB  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  IPCA LABS  

Compare SHASUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Sell-Off; Sensex Slumps Over 530 Points(Closing)

Share markets in India continued their sell-off seen during the last week and ended the day deep in the red. All sectoral indices traded on a negative note.

Related Views on News

FDC LTD. Announces Quarterly Results (1QFY19); Net Profit Up 74.5% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, FDC LTD. has posted a net profit of Rs 511 m (up 74.5% YoY). Sales on the other hand came in at Rs 3 bn (up 16.7% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

FDC LTD. Announces Quarterly Results (4QFY18); Net Profit Down 35.8% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, FDC LTD. has posted a net profit of Rs 315 m (down 35.8% YoY). Sales on the other hand came in at Rs 3 bn (up 5.9% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS